Maze Therapeutics announces encouraging initial human data from a Phase 1 trial involving healthy participants.

Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.

Kymera Therapeutics has begun administering doses to the initial participant in its Phase 1 clinical trial of KT-621.

Tonix Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for TNX-102 SL (Cyclobenzaprine hydrochloride).

Intellia Announces Encouraging Outcomes from Phase 2 Trial of NTLA-2002, a CRISPR Gene Editing Therapy for Hereditary Angioedema (HAE).

Longboard Pharmaceuticals has recently announced the initiation of the global Phase 3 DEEp SEA study.

Skyhawk Therapeutics showcases impressive preclinical findings for SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Treatments Symposium.

Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).

Accent Therapeutics has received FDA approval for its IND application for ATX-559, the first oral inhibitor targeting DHX9.

Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.

Tyra Biosciences has shared preliminary clinical proof-of-concept findings for TYRA-300, a selective oral FGFR3 inhibitor.

Schrödinger shared new preclinical findings on SGR-3515 during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024).